Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by shareswapperon Dec 11, 2020 9:38pm
114 Views
Post# 32091969

RE:RE:RE:Is Bill Gates Backing ICO????!!!

RE:RE:RE:Is Bill Gates Backing ICO????!!!From the companies Oct. 21st, 2020 press release;

"Although the Covid-19 pandemic is affecting clinical trials world-wide, iCo is actively preparing for a Phase 2 clinical study in vulvovaginal candidiasis) or, alternatively, in visceral leishmaniasis," stated Dr. Peter Hnik.

So if i'm reading this right, we could do a Phase II in Vulvovaginal Candidiasis with a Partner's backing or a Phase II in Leishmaniasis with a different Partner?  Leishmaniasis would require an International Partner (see the world=wide part) as this is a Tropical Disease predominent in India and Africa.  Vulvovaginal Candidiasis would likely be a N. America Partner.  If a Partner backed us in one area they would not want another Partner involved with the same Drug in another area.  Sounds to me like we have a couple options and would go with the best offer.  We know they have said they are Partnering, they do not have the money to run either on their own.  This is getting REALLY INTERESTING .... Hmmmmm .......




<< Previous
Bullboard Posts
Next >>